Cytokinetics Inc

Research Cytokinetics Inc (CYTK) on Bullrun: market cap USD 11.85B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCYTK
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 11.85B
• Financial periodFY2025
• RevenueUSD 88.04M
• Revenue growth376.6%
• Net income-USD 784.96M
• Free cash flow-USD 534.82M

Valuation Snapshot

latest market cap is USD 11.85B.

About Cytokinetics Inc

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM;

Frequently asked questions

What is Cytokinetics Inc's market cap?

Cytokinetics Inc's market capitalization is USD 11.85B.

What does Cytokinetics Inc do?

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.